These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 27936778)

  • 1. Computational Models of the Gastrointestinal Environment. 2. Phase Behavior and Drug Solubilization Capacity of a Type I Lipid-Based Drug Formulation after Digestion.
    Birru WA; Warren DB; Han S; Benameur H; Porter CJ; Pouton CW; Chalmers DK
    Mol Pharm; 2017 Mar; 14(3):580-592. PubMed ID: 27936778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Computational Models of the Gastrointestinal Environment. 1. The Effect of Digestion on the Phase Behavior of Intestinal Fluids.
    Birru WA; Warren DB; Headey SJ; Benameur H; Porter CJ; Pouton CW; Chalmers DK
    Mol Pharm; 2017 Mar; 14(3):566-579. PubMed ID: 28099023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toward the establishment of standardized in vitro tests for lipid-based formulations. 2. The effect of bile salt concentration and drug loading on the performance of type I, II, IIIA, IIIB, and IV formulations during in vitro digestion.
    Williams HD; Anby MU; Sassene P; Kleberg K; Bakala-N'Goma JC; Calderone M; Jannin V; Igonin A; Partheil A; Marchaud D; Jule E; Vertommen J; Maio M; Blundell R; Benameur H; Carrière F; Müllertz A; Pouton CW; Porter CJ
    Mol Pharm; 2012 Nov; 9(11):3286-300. PubMed ID: 23030411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug solubilization behavior during in vitro digestion of suspension formulations of poorly water-soluble drugs in triglyceride lipids.
    Kaukonen AM; Boyd BJ; Charman WN; Porter CJ
    Pharm Res; 2004 Feb; 21(2):254-60. PubMed ID: 15032306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phytantriol and glyceryl monooleate cubic liquid crystalline phases as sustained-release oral drug delivery systems for poorly water-soluble drugs II. In-vivo evaluation.
    Nguyen TH; Hanley T; Porter CJ; Larson I; Boyd BJ
    J Pharm Pharmacol; 2010 Jul; 62(7):856-65. PubMed ID: 20636873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug solubilization behavior during in vitro digestion of simple triglyceride lipid solution formulations.
    Kaukonen AM; Boyd BJ; Porter CJ; Charman WN
    Pharm Res; 2004 Feb; 21(2):245-53. PubMed ID: 15032305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential for drug supersaturation during intestinal processing of lipid-based formulations may be enhanced for basic drugs.
    Yeap YY; Trevaskis NL; Porter CJ
    Mol Pharm; 2013 Jul; 10(7):2601-15. PubMed ID: 23697606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Solubilisation behaviour of poorly water-soluble drugs during digestion of solid SMEDDS.
    Vithani K; Hawley A; Jannin V; Pouton C; Boyd BJ
    Eur J Pharm Biopharm; 2018 Sep; 130():236-246. PubMed ID: 29981444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Susceptibility to lipase-mediated digestion reduces the oral bioavailability of danazol after administration as a medium-chain lipid-based microemulsion formulation.
    Porter CJ; Kaukonen AM; Boyd BJ; Edwards GA; Charman WN
    Pharm Res; 2004 Aug; 21(8):1405-12. PubMed ID: 15359575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Digestion of phospholipids after secretion of bile into the duodenum changes the phase behavior of bile components.
    Birru WA; Warren DB; Ibrahim A; Williams HD; Benameur H; Porter CJ; Chalmers DK; Pouton CW
    Mol Pharm; 2014 Aug; 11(8):2825-34. PubMed ID: 24987935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An in vitro digestion test that reflects rat intestinal conditions to probe the importance of formulation digestion vs first pass metabolism in Danazol bioavailability from lipid based formulations.
    Anby MU; Nguyen TH; Yeap YY; Feeney OM; Williams HD; Benameur H; Pouton CW; Porter CJ
    Mol Pharm; 2014 Nov; 11(11):4069-83. PubMed ID: 25265395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative evaluation of mono-, di- and triglyceride of medium chain fatty acids by lipid/surfactant/water phase diagram, solubility determination and dispersion testing for application in pharmaceutical dosage form development.
    Prajapati HN; Dalrymple DM; Serajuddin AT
    Pharm Res; 2012 Jan; 29(1):285-305. PubMed ID: 21861203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro digestion testing of lipid-based delivery systems: calcium ions combine with fatty acids liberated from triglyceride rich lipid solutions to form soaps and reduce the solubilization capacity of colloidal digestion products.
    Devraj R; Williams HD; Warren DB; Mullertz A; Porter CJ; Pouton CW
    Int J Pharm; 2013 Jan; 441(1-2):323-33. PubMed ID: 23178598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug solubility in fatty acids as a formulation design approach for lipid-based formulations: a technical note.
    Lee YC; Dalton C; Regler B; Harris D
    Drug Dev Ind Pharm; 2018 Sep; 44(9):1551-1556. PubMed ID: 29873584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlating in Vitro Solubilization and Supersaturation Profiles with in Vivo Exposure for Lipid Based Formulations of the CETP Inhibitor CP-532,623.
    McEvoy CL; Trevaskis NL; Feeney OM; Edwards GA; Perlman ME; Ambler CM; Porter CJH
    Mol Pharm; 2017 Dec; 14(12):4525-4538. PubMed ID: 29076741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipid-based formulations to enhance oral bioavailability of the poorly water-soluble drug anethol trithione: effects of lipid composition and formulation.
    Han SF; Yao TT; Zhang XX; Gan L; Zhu C; Yu HZ; Gan Y
    Int J Pharm; 2009 Sep; 379(1):18-24. PubMed ID: 19508887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of lipid-based SEDDS using digestion products of long-chain triglyceride for high drug solubility: Formulation and dispersion testing.
    Desai HH; T M Serajuddin A
    Int J Pharm; 2024 Apr; 654():123953. PubMed ID: 38417725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Dynamics Simulations and Experimental Results Provide Insight into Clinical Performance Differences between Sandimmune® and Neoral® Lipid-Based Formulations.
    Warren DB; Haque S; McInerney MP; Corbett KM; Kastrati E; Ford L; Williams HD; Jannin V; Benameur H; Porter CJH; Chalmers DK; Pouton CW
    Pharm Res; 2021 Sep; 38(9):1531-1547. PubMed ID: 34561814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increasing the proportional content of surfactant (Cremophor EL) relative to lipid in self-emulsifying lipid-based formulations of danazol reduces oral bioavailability in beagle dogs.
    Cuiné JF; Charman WN; Pouton CW; Edwards GA; Porter CJ
    Pharm Res; 2007 Apr; 24(4):748-57. PubMed ID: 17372700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 'Stealth' lipid-based formulations: poly(ethylene glycol)-mediated digestion inhibition improves oral bioavailability of a model poorly water soluble drug.
    Feeney OM; Williams HD; Pouton CW; Porter CJ
    J Control Release; 2014 Oct; 192():219-27. PubMed ID: 25058571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.